{"id":22386,"date":"2023-04-21T21:54:50","date_gmt":"2023-04-21T16:24:50","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=22386"},"modified":"2024-10-28T15:54:43","modified_gmt":"2024-10-28T10:24:43","slug":"respiratory-syncytial-virus-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment","title":{"rendered":"Respiratory Syncytial Virus Treatment Market: A Complex Space Worth Billions!"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e0040ee6feb\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e0040ee6feb\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment\/#Current_respiratory_syncytial_virus_therapies_their_challenges_and_upcoming_therapies\" >Current respiratory syncytial virus therapies, their challenges, and upcoming therapies&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment\/#The_adult_respiratory_syncytial_virus_treatment_market_is_lucrative_enough_to_be_eyed_on\" >The adult respiratory syncytial virus treatment market is lucrative enough to be eyed on<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment\/#FDA_advisers_in_favor_of_GSKs_Product\" >FDA advisers in favor of GSK\u2019s Product?&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment\/#The_potential_risk_factors_and_challenges_of_these_respiratory_syncytial_virus_vaccines\" >The potential risk factors and challenges of these respiratory syncytial virus vaccines<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Respiratory syncytial virus is estimated to affect approximately <strong>5 million <\/strong>cases this year in the United States and <strong>2.5 million<\/strong> RSV cases in the EU4 countries and the United Kingdom. As per Delveinsight analysis on the latest published \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-epidemiology-forecast\"><strong>Respiratory Syncytial Virus Epidemiology Report<\/strong><\/a>,\u201d the US comprised <strong>~70%, ~27%, and ~3%<\/strong> of the total number of mild, moderate, and severe cases of respiratory syncytial virus in children, respectively, in 2022. Whereas <strong>~17%, ~64%, and ~19%<\/strong> of the mild, moderate, and severe cases of respiratory syncytial virus in adults, respectively, in 2022.<\/p>\n\n\n\n<p>Despite such a high number of incident cases, there is still a high unmet need for effective respiratory syncytial virus treatment. This condition seems to have troubled drug makers for decades. Many clinical attempts failed miserably, raising a question about understanding the disease and its mechanism.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-current-respiratory-syncytial-virus-therapies-their-challenges-and-upcoming-therapies-nbsp\"><span class=\"ez-toc-section\" id=\"Current_respiratory_syncytial_virus_therapies_their_challenges_and_upcoming_therapies\"><\/span><strong>Current respiratory syncytial virus therapies, their challenges, and upcoming therapies&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The respiratory syncytial virus treatment is majorly supportive, with no approved drug for adults; in infants, <strong>Ribavirin<\/strong> and <strong>Synagis (palivizumab)<\/strong> were approved by the US FDA for <a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-market\">respiratory syncytial virus treatment<\/a>.&nbsp;<\/p>\n\n\n\n<p><strong>Synagis<\/strong> is only used <strong>prophylactically<\/strong> for high-risk groups and comes up with many challenges, such as high cost, frequent administrations, and many more. After tremendous hard work, <strong>Sanofi and AstraZeneca\u2019s <\/strong>&nbsp;<strong>Beyfortus (nirsevimab)<\/strong> got approved by the <a href=\"https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/beyfortus-approved-in-the-eu-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants.html\">European Union<\/a>&nbsp;to prevent RSV lower respiratory tract disease in newborns and infants. The respiratory syncytial virus vaccine addressed the challenges which were there with palivizumab.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/respiratory-syncytial-virus-rsv-market\"><img decoding=\"async\" width=\"613\" height=\"361\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20183737\/respiratory-syncytial-virus-infographics.png\" alt=\"respiratory syncytial virus infographics\" class=\"wp-image-22396\" style=\"width:460px;height:271px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20183737\/respiratory-syncytial-virus-infographics.png 613w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20183737\/respiratory-syncytial-virus-infographics-300x177.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20183737\/respiratory-syncytial-virus-infographics-150x88.png 150w\" sizes=\"(max-width: 613px) 100vw, 613px\" \/><\/a><\/figure>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>A single dose of<\/em><\/strong><strong> <\/strong><strong><em>Beyfortus is required for the entire RSV season, making it a more convenient option than Synagis, which requires monthly administration for the entire RSV season. As per the DelveInsight analyst, the drug is estimated to cost ~USD 200\u2013350 per patient, which is very low compared to <\/em><\/strong><strong>palivizumab<\/strong><strong><em>, thus addressing the cost barrier. This immunization technique will change the preventive regime and focus on the broad newborn and infant population, which was a limitation in Synagis.&nbsp;<\/em><\/strong><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>\u201cBeyfortus is estimated to gain a peak patient share of 50% in the United States with an estimated 4 million patients to be treated at its peak\u201d. \u2013 Delveinsight Analysts<\/em><\/strong><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_adult_respiratory_syncytial_virus_treatment_market_is_lucrative_enough_to_be_eyed_on\"><\/span><strong>The adult respiratory syncytial virus treatment market is lucrative enough to be eyed on<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>With a potential immunization technique for infants, the adult <a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-market\">respiratory syncytial virus treatment market<\/a> seems very lucrative and can become bigger in the upcoming years.&nbsp; RSV in adults is managed by supportive respiratory syncytial virus treatment and tends to affect the older population adversely; this is because the older adult has comorbidities that stir up the RSV response and increases hospitalization.&nbsp;<\/p>\n\n\n\n<p>To address these challenges, big pharma companies such as <strong>GSK<\/strong> and <strong>Pfizer<\/strong> are soon bringing the first respiratory syncytial virus vaccine to the older adult population.<em>&nbsp;<\/em><\/p>\n\n\n\n<p><strong>GSK respiratory syncytial virus vaccine<\/strong> outperformed the <strong>Pfizer respiratory syncytial virus vaccine<\/strong> with strong efficacy results<em>. <\/em>In severe RSV-associated lower respiratory tract illness (LRTI-RSV), there was a 94.1% reduction in the infection. In participants with pre-existing comorbidities, such as underlying cardiorespiratory and endocrine metabolic conditions, vaccine efficacy was <strong>94.6%, with 93.8% <\/strong>efficacy observed in adults aged 70\u201379. Pfizer\u2019s RSVpreF vaccine showed an efficacy of <strong>66.7%<\/strong> in patients with LRTI-RSV defined by two or more symptoms; in more severe diseases where endpoints of LRTI-RSV defined by three or more symptoms, the vaccine showed an efficacy of 85.7%.<\/p>\n\n\n\n<p>Both respiratory syncytial virus vaccines showed enough promising results to get likely approval from the US FDA later this year.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_advisers_in_favor_of_GSKs_Product\"><\/span><strong>FDA advisers in favor of GSK\u2019s Product?&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The PDUFA date of May 2023 is set for both <strong>Pfizer and GSK<\/strong>, and they are all set to launch the <a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-pipeline-insight\">respiratory syncytial virus drug<\/a> with no supply issues as soon as it gets approval. The drug maker has also applied for approval in the European Union and Japan.&nbsp;<\/p>\n\n\n\n<p>As per the latest Food and Drug Administration\u2019s independent panel of advisors, the Pfizer vaccine gained a 7\u20134 in favor of the committee for the safety and efficacy assessment. GSK\u2019s vaccine was given 10\u20132 in favor of safety and unanimously for efficacy.&nbsp;<\/p>\n\n\n\n<p>The high efficacy results in patients with underlying conditions may have given GSK\u2019s product an additional edge over others. The respiratory syncytial virus vaccine also showed good efficacy when administered with the Flu vaccine.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_potential_risk_factors_and_challenges_of_these_respiratory_syncytial_virus_vaccines\"><\/span><strong>The potential risk factors and challenges of these respiratory syncytial virus vaccines<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>With so much going around their approval, both <a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-pipeline-insight\">respiratory syncytial virus vaccines<\/a> have shown some serious cases of Guillain\u2013Barre syndrome, a serious health concern; therefore, post-marketing data and additional safety studies are required to undercover the additional safety concerns<em>.<\/em>&nbsp;<\/p>\n\n\n\n<p>With so many promises being done, the efficacy of the respiratory syncytial virus vaccines in 80 years and the above population is also something to be looked for. GSK\u2019s respiratory syncytial virus vaccines have not shown very promising results in this age group, and Pfizer\u2019s detailed results are still awaited; hence there still lies an unmet need, as most patients are at high risk of RSV and have many comorbidities.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" width=\"1024\" height=\"464\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20183905\/Respiratory-Syncytial-Virus-Emerging-Therapies-and-Vaccines-1024x464.png\" alt=\"Respiratory Syncytial Virus Emerging Therapies and Vaccines\" class=\"wp-image-22397\" style=\"width:768px;height:348px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20183905\/Respiratory-Syncytial-Virus-Emerging-Therapies-and-Vaccines-1024x464.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20183905\/Respiratory-Syncytial-Virus-Emerging-Therapies-and-Vaccines-300x136.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20183905\/Respiratory-Syncytial-Virus-Emerging-Therapies-and-Vaccines-150x68.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20183905\/Respiratory-Syncytial-Virus-Emerging-Therapies-and-Vaccines-768x348.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20183905\/Respiratory-Syncytial-Virus-Emerging-Therapies-and-Vaccines.png 1066w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>With such tough competition, seeing these <a href=\"https:\/\/www.delveinsight.com\/infographics\/respiratory-syncytial-virus-rsv-market\">respiratory syncytial virus drugs\u2019 uptake<\/a> and response in the upcoming years would be interesting. We have Moderna and a few other companies in the queue. <strong>Moderna<\/strong> has recently announced the Phase III topline data results with a vaccine efficacy of <strong>83.7%<\/strong>. The company is yet to submit for regulatory approval.<\/p>\n\n\n\n<p><strong>GSK and Pfizer<\/strong> have already set some high bars for the upcoming vaccines to capture the respiratory syncytial virus treatment market worth billions. Companies must have exceptional safety and efficacy results and may fill safety and efficacy loopholes in the existing players to make their product a blockbuster.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>Delveinsight estimates suggest that the RSVPreF3 vaccine is estimated to generate a revenue of more than 1 billion at its peak, while RSVPreF could be anywhere between USD 800 million to 1 billion for the same in the United States.<\/em><\/strong><\/p>\n<\/blockquote>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"781\" height=\"358\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182750\/Estimated-revenue-in-million-of-the-upcoming-vaccines-in-the-US.png\" alt=\"Estimated revenue (in-million) of the upcoming vaccines in the US\" class=\"wp-image-22395\" style=\"width:586px;height:269px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182750\/Estimated-revenue-in-million-of-the-upcoming-vaccines-in-the-US.png 781w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182750\/Estimated-revenue-in-million-of-the-upcoming-vaccines-in-the-US-300x138.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182750\/Estimated-revenue-in-million-of-the-upcoming-vaccines-in-the-US-150x69.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182750\/Estimated-revenue-in-million-of-the-upcoming-vaccines-in-the-US-768x352.png 768w\" sizes=\"(max-width: 781px) 100vw, 781px\" \/><\/figure>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>As per the estimates, once approved, GSK\u2019s vaccine is estimated to capture a market of 24% in the next 10 years, with approximately 5 million patients can be vaccinated by it in the United States alone.&nbsp;<\/em><\/strong><\/p>\n<\/blockquote>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" width=\"781\" height=\"189\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182709\/Estimated-Market-share-of-Upcoming-RSV-Vaccines-in-the-United-States.png\" alt=\"Estimated Market share of Upcoming RSV Vaccines in the United States\" class=\"wp-image-22394\" style=\"width:586px;height:142px\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182709\/Estimated-Market-share-of-Upcoming-RSV-Vaccines-in-the-United-States.png 781w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182709\/Estimated-Market-share-of-Upcoming-RSV-Vaccines-in-the-United-States-300x73.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182709\/Estimated-Market-share-of-Upcoming-RSV-Vaccines-in-the-United-States-150x36.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182709\/Estimated-Market-share-of-Upcoming-RSV-Vaccines-in-the-United-States-768x186.png 768w\" sizes=\"(max-width: 781px) 100vw, 781px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1681994928963\"><strong class=\"schema-faq-question\"><strong>1. What is a respiratory syncytial virus?<\/strong><\/strong> <p class=\"schema-faq-answer\">The respiratory syncytial virus (RSV) is a highly contagious respiratory virus. It belongs to the genus <em>Pneumovirus<\/em>, which is part of the family Paramyxoviridae. Virus particles are enveloped and pleomorphic, forming irregular spherical particles with diameters of 100-350 nm and long filamentous fibers with diameters of 60-200 nm and lengths of 10 mm.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1681994947240\"><strong class=\"schema-faq-question\"><strong>2. What are respiratory syncytial virus symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">Signs and symptoms of respiratory syncytial virus infection typically appear 46 days after virus exposure. RSV typically causes mild cold-like symptoms in adults and older children. These respiratory syncytial virus symptoms may include a stuffy or runny nose, a dry cough, a low-grade fever, sore throat, sneezing, and a headache.\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1681994958672\"><strong class=\"schema-faq-question\"><strong>3. How is respiratory syncytial virus diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">RSV testing is not always necessary. Several types of laboratory tests are used for respiratory syncytial virus diagnosis if required. The rapid diagnostic test is the most commonly used.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1681994969496\"><strong class=\"schema-faq-question\"><strong>4. What are the current respiratory syncytial virus treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">The mainstay respiratory syncytial virus treatment for bronchiolitis is supportive care. Most infants may be treated at home, but those who appear unwell, are dehydrated, have poor feeding or apnea, suffer respiratory distress, or require supplemental oxygen should be hospitalized. The average length of stay in the hospital is 3-7 days.<\/p> <\/div> <\/div>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/respiratory-syncytial-virus-rsv-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/28155246\/Respiratory-Syncytial-Virus-Market-Outlook-1024x194.png\" alt=\"Respiratory-Syncytial-Virus-Market-Outlook\" class=\"wp-image-30170\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/28155246\/Respiratory-Syncytial-Virus-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/28155246\/Respiratory-Syncytial-Virus-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/28155246\/Respiratory-Syncytial-Virus-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/28155246\/Respiratory-Syncytial-Virus-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/28155246\/Respiratory-Syncytial-Virus-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/28155246\/Respiratory-Syncytial-Virus-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Respiratory syncytial virus is estimated to affect approximately 5 million cases this year in the United States and 2.5 million RSV cases in the EU4 countries and the United Kingdom. As per Delveinsight analysis on the latest published \u201cRespiratory Syncytial Virus Epidemiology Report,\u201d the US comprised ~70%, ~27%, and ~3% of the total number of [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":22390,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":5,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[985,460,17615,2009,20608,20609,20611,20610],"industry":[17225],"therapeutic_areas":[17231,17243],"class_list":["post-22386","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-glaxosmithkline","tag-pfizer","tag-respiratory-syncytial-virus","tag-respiratory-syncytial-virus-rsv","tag-respiratory-syncytial-virus-treatment","tag-respiratory-syncytial-virus-vaccines","tag-rsvpref","tag-rsvpref3-vaccine","industry-pharmaceutical","therapeutic_areas-infectious-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Emerging Vaccine for Respiratory Syncytial Virus Treatment<\/title>\n<meta name=\"description\" content=\"To address challenges, pharma giants GSK &amp; Pfizer are bringing first vaccine for respiratory syncytial virus treatment to adult population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emerging Vaccine for Respiratory Syncytial Virus Treatment\" \/>\n<meta property=\"og:description\" content=\"To address challenges, pharma giants GSK &amp; Pfizer are bringing first vaccine for respiratory syncytial virus treatment to adult population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-21T16:24:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-28T10:24:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182352\/emerging-vaccines-for-respiratory-syncytial-virus-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Emerging Vaccine for Respiratory Syncytial Virus Treatment","description":"To address challenges, pharma giants GSK & Pfizer are bringing first vaccine for respiratory syncytial virus treatment to adult population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment","og_locale":"en_US","og_type":"article","og_title":"Emerging Vaccine for Respiratory Syncytial Virus Treatment","og_description":"To address challenges, pharma giants GSK & Pfizer are bringing first vaccine for respiratory syncytial virus treatment to adult population.","og_url":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-04-21T16:24:50+00:00","article_modified_time":"2024-10-28T10:24:43+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182352\/emerging-vaccines-for-respiratory-syncytial-virus-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment","url":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment","name":"Emerging Vaccine for Respiratory Syncytial Virus Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182352\/emerging-vaccines-for-respiratory-syncytial-virus-treatment.png","datePublished":"2023-04-21T16:24:50+00:00","dateModified":"2024-10-28T10:24:43+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"To address challenges, pharma giants GSK & Pfizer are bringing first vaccine for respiratory syncytial virus treatment to adult population.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#faq-question-1681994928963"},{"@id":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#faq-question-1681994947240"},{"@id":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#faq-question-1681994958672"},{"@id":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#faq-question-1681994969496"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182352\/emerging-vaccines-for-respiratory-syncytial-virus-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182352\/emerging-vaccines-for-respiratory-syncytial-virus-treatment.png","width":772,"height":482,"caption":"emerging-vaccines-for-respiratory-syncytial-virus-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#faq-question-1681994928963","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#faq-question-1681994928963","name":"1. What is a respiratory syncytial virus?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The respiratory syncytial virus (RSV) is a highly contagious respiratory virus. It belongs to the genus <em>Pneumovirus<\/em>, which is part of the family Paramyxoviridae. Virus particles are enveloped and pleomorphic, forming irregular spherical particles with diameters of 100-350 nm and long filamentous fibers with diameters of 60-200 nm and lengths of 10 mm.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#faq-question-1681994947240","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#faq-question-1681994947240","name":"2. What are respiratory syncytial virus symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Signs and symptoms of respiratory syncytial virus infection typically appear 46 days after virus exposure. RSV typically causes mild cold-like symptoms in adults and older children. These respiratory syncytial virus symptoms may include a stuffy or runny nose, a dry cough, a low-grade fever, sore throat, sneezing, and a headache.\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#faq-question-1681994958672","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#faq-question-1681994958672","name":"3. How is respiratory syncytial virus diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"RSV testing is not always necessary. Several types of laboratory tests are used for respiratory syncytial virus diagnosis if required. The rapid diagnostic test is the most commonly used.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#faq-question-1681994969496","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/respiratory-syncytial-virus-treatment#faq-question-1681994969496","name":"4. What are the current respiratory syncytial virus treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The mainstay respiratory syncytial virus treatment for bronchiolitis is supportive care. Most infants may be treated at home, but those who appear unwell, are dehydrated, have poor feeding or apnea, suffer respiratory distress, or require supplemental oxygen should be hospitalized. The average length of stay in the hospital is 3-7 days.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/04\/20182352\/emerging-vaccines-for-respiratory-syncytial-virus-treatment-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Respiratory Syncytial Virus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">respiratory syncytial virus (RSV)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Respiratory Syncytial Virus treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Respiratory Syncytial Virus Vaccines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">RSVPreF<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">RSVPreF3 vaccine<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Respiratory Syncytial Virus<\/span>","<span class=\"advgb-post-tax-term\">respiratory syncytial virus (RSV)<\/span>","<span class=\"advgb-post-tax-term\">Respiratory Syncytial Virus treatment<\/span>","<span class=\"advgb-post-tax-term\">Respiratory Syncytial Virus Vaccines<\/span>","<span class=\"advgb-post-tax-term\">RSVPreF<\/span>","<span class=\"advgb-post-tax-term\">RSVPreF3 vaccine<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Apr 21, 2023","modified":"Updated on Oct 28, 2024"},"absolute_dates_time":{"created":"Posted on Apr 21, 2023 9:54 pm","modified":"Updated on Oct 28, 2024 3:54 pm"},"featured_img_caption":"emerging-vaccines-for-respiratory-syncytial-virus-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/22386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=22386"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/22386\/revisions"}],"predecessor-version":[{"id":30173,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/22386\/revisions\/30173"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/22390"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=22386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=22386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=22386"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=22386"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=22386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}